You are here

Our science / Clinical Trials / Find a Trial / NCT00544557

Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis

Back to Search Print Save as PDF Bookmark Trial

NCT00544557

Last updated on May 11, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Klinikum Benjamin Franklin
Berlin, , 12200 Germany
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Ankylosing Spondylitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of ankylosing spondylitis (AS)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Hypersensitivity to etanercept

- Active infection including chronic or localised infection

- Sepsis or risk of sepsis

NCT00544557
Pfizer
Completed
Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Ankylosing Spondylitis
Etanercept Withdrawal And Retreatment Study In Subjects With Non- Radiographic Axial Spondyloarthritis (Chronic Lower Back Pain)
NCT02509026
All Genders
18+
Years
Multiple Sites
Ankylosing Spondylitis, Psoriatic Arthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis
NCT00273858
All Genders
18+
Years
Multiple Sites
Ankylosing Spondylitis
Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis
NCT01786668
All Genders
18+
Years
Multiple Sites
Ankylosing Spondylitis
Defining Remission With Etanercept in AS in Real Life Clinical Practice
NCT02202850
All Genders
18+
Years
Multiple Sites
Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis
Observational Study Of The Use Of Enbrel (Registered) (Etanercept) In Routine Clinical Practice To Treat Ankylosing Spondylitis (as) Patients: An Effectiveness, Safety, And Health Economic Evaluation
This study aims to provide a holistic assessment of patients receiving etanercept in a real-world setting.
Non-interventional study: subjects to be selected according to the usual clinical practice of their physician
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients with an established diagnosis of Ankylosing Spondylitis
Ankylosing Spondylitis
Drug: Etanercept
The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Other Name: Enbrel
Patients with Ankylosing Spondylitis
Intervention: Drug: Etanercept
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1715
May 2014
May 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of ankylosing spondylitis (AS)

Exclusion Criteria:

  • Hypersensitivity to etanercept
  • Active infection including chronic or localised infection
  • Sepsis or risk of sepsis
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT00544557
0881X1-4463
B1801087 ( Other Identifier: Alias Study Number )
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
April 2015

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now